Sensus Healthcare (NASDAQ:SRTS) Issues Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Sensus Healthcare (NASDAQ:SRTS) posted its quarterly earnings data on Thursday. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.10), Zacks reports. Sensus Healthcare had a negative net margin of 8.44% and a negative return on equity of 5.67%.

Here are the key takeaways from Sensus Healthcare’s conference call:

• New dedicated CPT codes for SRT and IG‑SRT effective 1/1/2026 provide clear, enhanced reimbursement and management said this removes a major adoption barrier for non‑invasive skin cancer treatment.
• Financials weakened materially in 2025 with Q4 revenue of $4.9M (vs. $31M a year earlier), full‑year revenue of $27.5M (vs. $41.8M), a $7.7M net loss and Adjusted EBITDA of -$9.6M, driven largely by reduced sales to their largest customer.
• Balance sheet and outlook: the company ended 2025 with $22.1M cash, no debt, elevated inventory to support demand, expects Q1 shipments to exceed Q4 levels (excluding the largest customer) and targets full‑year profitability in 2026.
• Fair Deal (FDA placement) program momentum: 18 active sites and 10 pending, with treatments up ~8x and patients treated up >250% year‑over‑year, which management says is converting into outright purchases in some cases.
• Product and regulatory uncertainty remains—TDI approval timing is unclear and R&D expense rose to $7.8M as the company invests in next‑generation systems and billing/reimbursement efforts, posing near‑term execution and cost risks.

Sensus Healthcare Trading Down 2.3%

NASDAQ:SRTS traded down $0.11 during mid-day trading on Thursday, reaching $4.65. The company’s stock had a trading volume of 146,783 shares, compared to its average volume of 106,593. The firm’s fifty day moving average price is $4.45 and its two-hundred day moving average price is $3.93. Sensus Healthcare has a 12-month low of $3.03 and a 12-month high of $5.92. The stock has a market cap of $76.38 million, a P/E ratio of -24.47 and a beta of 1.21.

Insider Buying and Selling

In related news, Director Eric Sachetta acquired 7,000 shares of the firm’s stock in a transaction dated Friday, November 21st. The shares were purchased at an average price of $3.93 per share, with a total value of $27,510.00. Following the completion of the purchase, the director directly owned 140,113 shares of the company’s stock, valued at $550,644.09. This represents a 5.26% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Joseph C. Sardano purchased 25,000 shares of the firm’s stock in a transaction on Tuesday, November 18th. The shares were acquired at an average cost of $4.03 per share, for a total transaction of $100,750.00. Following the completion of the acquisition, the chief executive officer owned 1,200,293 shares of the company’s stock, valued at approximately $4,837,180.79. This trade represents a 2.13% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders purchased 33,000 shares of company stock worth $132,060. 8.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Sensus Healthcare

An institutional investor recently raised its position in Sensus Healthcare stock. Geode Capital Management LLC lifted its position in Sensus Healthcare, Inc. (NASDAQ:SRTS) by 3.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 158,240 shares of the company’s stock after purchasing an additional 5,316 shares during the period. Geode Capital Management LLC owned 0.96% of Sensus Healthcare worth $630,000 at the end of the most recent quarter. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SRTS has been the topic of a number of research reports. Zacks Research raised shares of Sensus Healthcare from a “strong sell” rating to a “hold” rating in a report on Wednesday, October 22nd. Weiss Ratings restated a “sell (d)” rating on shares of Sensus Healthcare in a research report on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of Sensus Healthcare from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Sensus Healthcare presently has a consensus rating of “Hold” and an average target price of $8.00.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.